275 related articles for article (PubMed ID: 22510356)
21. Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events.
Stebbing J; Waters L; Mandalia S; Bower M; Nelson M; Gazzard B
Clin Infect Dis; 2005 Sep; 41(6):906-11. PubMed ID: 16107994
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis C and progression of HIV disease.
Sulkowski MS; Moore RD; Mehta SH; Chaisson RE; Thomas DL
JAMA; 2002 Jul; 288(2):199-206. PubMed ID: 12095384
[TBL] [Abstract][Full Text] [Related]
23. Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCV-coinfected patients under highly active antiretroviral treatment.
de Larrañaga GF; Wingeyer SD; Puga LM; Alonso BS; Benetucci JA
Eur J Clin Microbiol Infect Dis; 2006 Feb; 25(2):98-103. PubMed ID: 16477441
[TBL] [Abstract][Full Text] [Related]
24. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy.
Yacisin K; Maida I; Ríos MJ; Soriano V; Núñez M
AIDS Res Hum Retroviruses; 2008 Jul; 24(7):935-40. PubMed ID: 18593347
[TBL] [Abstract][Full Text] [Related]
26. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.
Braitstein P; Zala C; Yip B; Brinkhof MW; Moore D; Hogg RS; Montaner JS
J Infect Dis; 2006 Jan; 193(2):259-68. PubMed ID: 16362890
[TBL] [Abstract][Full Text] [Related]
27. Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database.
Petoumenos K; Ringland C;
HIV Med; 2005 May; 6(3):155-63. PubMed ID: 15876281
[TBL] [Abstract][Full Text] [Related]
28. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
29. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting.
Reiberger T; Obermeier M; Payer BA; Baumgarten A; Weitner L; Moll A; Christensen S; Köppe S; Kundi M; Rieger A; Peck-Radosavljevic M
Antivir Ther; 2011; 16(6):815-24. PubMed ID: 21900713
[TBL] [Abstract][Full Text] [Related]
30. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus.
Martinez-Sierra C; Arizcorreta A; Díaz F; Roldán R; Martín-Herrera L; Pérez-Guzmán E; Girón-González JA
Clin Infect Dis; 2003 Feb; 36(4):491-8. PubMed ID: 12567308
[TBL] [Abstract][Full Text] [Related]
31. Determinants of immunological and virological responses to antiretroviral therapy amongst HIV-infected adults in central Argentina: negative influence of hepatitis C infection.
Farías AA; Kremer LE; Allende L; Díaz Mdel P; Pisano MB; Contigiani MS; Ré VE
Trans R Soc Trop Med Hyg; 2013 Jul; 107(7):432-7. PubMed ID: 23761392
[TBL] [Abstract][Full Text] [Related]
32. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
Phillips E; Gutiérrez S; Jahnke N; Yip B; Lima VD; Hogg RS; Harrigan PR; Montaner JS
AIDS; 2007 Jul; 21(12):1561-8. PubMed ID: 17630551
[TBL] [Abstract][Full Text] [Related]
33. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015.
Sun J; Althoff KN; Jing Y; Horberg MA; Buchacz K; Gill MJ; Justice AC; Rabkin CS; Goedert JJ; Sigel K; Cachay E; Park L; Lim JK; Kim HN; Lo Re V; Moore R; Sterling T; Peters MG; Achenbach CJ; Silverberg M; Thorne JE; Mayor AM; Crane HM; Kitahata MM; Klein M; Kirk GD;
JAMA Netw Open; 2021 Feb; 4(2):e2037512. PubMed ID: 33595662
[TBL] [Abstract][Full Text] [Related]
34. Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients.
Suárez-Zarracina T; Valle-Garay E; Collazos J; Montes AH; Cárcaba V; Carton JA; Asensi V
J Viral Hepat; 2012 Oct; 19(10):685-93. PubMed ID: 22967099
[TBL] [Abstract][Full Text] [Related]
35. High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART?
Bani-Sadr F; Goderel I; Morand P; Payan C; Lunel F; Pol S; Perronne C; Carrat F; Cacoub P
AIDS; 2007 Jul; 21(12):1645-8. PubMed ID: 17630563
[TBL] [Abstract][Full Text] [Related]
36. Continued Substance Use Among People Living With HIV-Hepatitis-C Co-Infection and Receiving Antiretroviral Therapy.
Kalichman SC; Washington C; Kegler C; Grebler T; Kalichman MO; Cherry C; Eaton L
Subst Use Misuse; 2015; 50(12):1536-43. PubMed ID: 26583598
[TBL] [Abstract][Full Text] [Related]
37. [Chronic hepatitis C in patients with HIV/HCV coinfection with high CD4+ lymphocytes count].
Inglot M; Szymczak A; Gładysz A; Małyszczak K; Zalewska M
Przegl Epidemiol; 2007; 61(3):535-43. PubMed ID: 18069391
[TBL] [Abstract][Full Text] [Related]
38. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
[TBL] [Abstract][Full Text] [Related]
39. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.
Rockstroh JK; Bhagani S; Benhamou Y; Bruno R; Mauss S; Peters L; Puoti M; Soriano V; Tural C;
HIV Med; 2008 Feb; 9(2):82-8. PubMed ID: 18257771
[TBL] [Abstract][Full Text] [Related]
40. HIV infection and antiretroviral therapy: effect on hepatitis C virus quasispecies variability.
Shuhart MC; Sullivan DG; Bekele K; Harrington RD; Kitahata MM; Mathisen TL; Thomassen LV; Emerson SS; Gretch DR
J Infect Dis; 2006 May; 193(9):1211-8. PubMed ID: 16586356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
